Welcome to our dedicated page for Corcept Therapeutics news (Ticker: CORT), a resource for investors and traders seeking the latest updates and insights on Corcept Therapeutics stock.
Corcept Therapeutics Inc. (symbol: CORT) is a pioneering pharmaceutical company focused on the discovery and development of medications that modulate the effects of cortisol to treat severe metabolic, oncologic, and neuropsychiatric disorders. Since its inception, Corcept has dedicated itself to understanding and mitigating the adverse effects of excess cortisol, which plays a role in a variety of diseases.
The company has made significant strides in this field by developing over 300 proprietary molecules. These compounds competitively block the glucocorticoid receptor (GR) without affecting the progesterone receptor. Scientific studies suggest that GR antagonism may help treat conditions such as post-traumatic stress disorder, mild cognitive impairment, Alzheimer's disease, and alcoholism.
Corcept's flagship product, mifepristone, is already making an impact in the market. Additionally, the company continues to advance the most promising compounds from its extensive pipeline into clinical trials to assess their potential in mitigating the effects of excess cortisol and treating serious, sometimes life-threatening conditions.
Corcept's recent achievements include a series of successful clinical trials and partnerships that have bolstered its position in the pharmaceutical industry. Financially, the company is on stable ground, allowing it to invest further in research and development to expand its portfolio of effective treatments.
As a commercial-stage company, Corcept Therapeutics is committed to bringing innovative treatments to market, guided by a deep understanding of cortisol’s role in various diseases. Investors and healthcare professionals alike are keenly watching Corcept for its continued contributions to medical science and patient care.
For the latest updates on Corcept Therapeutics, including performance, events, and developments, please visit their official website or contact their investor relations team.
Corcept Therapeutics announced results from the prevalence phase of their CATALYST clinical trial at the American Diabetes Association’s 84th Scientific Sessions.
The trial enrolled 1,055 patients with difficult-to-control type 2 diabetes across 36 U.S. sites, making it the largest study of its kind. The results showed a 24% prevalence rate of hypercortisolism among these patients, a higher figure than previously assumed.
Hypercortisolism was notably common in patients with cardiovascular issues and those needing multiple medications for diabetes and hypertension control.
This new data may lead to better diagnosis and treatment strategies for hypercortisolism, a serious condition often overlooked in type 2 diabetes management.
Details of the treatment phase, where eligible patients received either Korlym or a placebo, are expected by year-end.
Corcept Therapeutics (NASDAQ: CORT) announced that results from the Phase 3 GRACE trial of relacorilant, a selective cortisol modulator for treating hypercortisolism (Cushing’s syndrome), will be presented at two major conferences in June 2024. The presentations will take place at the Endocrine Society (ENDO) annual meeting in Boston on June 3, and at the Heart in Diabetes (HiD) conference in Philadelphia on June 7. Key findings will be shared by Dr. Rosario Pivonello and Dr. Ralph DeFronzo, highlighting the impact of relacorilant on hypertension and hyperglycemia. Detailed results will be accessible on Corcept’s website post-events.
Corcept Therapeutics (NASDAQ: CORT) announced positive results from its Phase 3 GRACE trial of relacorilant for treating hypercortisolism (Cushing’s syndrome). The trial met its primary endpoint, showing significant improvements in hypertension, hyperglycemia, and other symptoms. In the randomized withdrawal phase, patients receiving relacorilant had a notably lower loss of blood pressure control compared to those on placebo (odds ratio: 0.17; p-value: 0.02). The drug was well-tolerated, with no significant safety differences observed. Corcept plans to submit a New Drug Application in Q3, with additional data presentations scheduled for June.
Corcept Therapeutics Incorporated reported strong financial results for the first quarter of 2024, with a revenue of $146.8 million, a 39% increase from the same period in 2023. The company raised its 2024 revenue guidance to $620 - $650 million and reported a net income per common share of $0.25. Corcept continues to focus on developing medications for various disorders by modulating the effects of cortisol. The company highlighted record numbers of new prescribers and patients for its drug Korlym in the first quarter, showcasing its growing presence in the market.
Corcept Therapeutics Incorporated has completed enrollment in the Phase 4 CATALYST trial, the largest study ever conducted to establish the prevalence of hypercortisolism in patients with difficult-to-control type 2 diabetes. Approximately 25% of the over 1,000 patients enrolled were identified as having hypercortisolism, a higher rate than previously assumed. Final prevalence data will be shared at the American Diabetes Association’s 84th Scientific Sessions in June, with treatment data expected by year-end. The findings from CATALYST aim to improve the identification and treatment of patients with hypercortisolism.
FAQ
What is the current stock price of Corcept Therapeutics (CORT)?
What is the market cap of Corcept Therapeutics (CORT)?
What does Corcept Therapeutics Inc. do?
What is the primary focus of Corcept Therapeutics' research?
What are some of the conditions Corcept's products aim to treat?
What is mifepristone?
How many proprietary molecules has Corcept developed?
Does Corcept Therapeutics have any ongoing clinical trials?
Are there any recent achievements by Corcept Therapeutics?
What is the financial condition of Corcept Therapeutics?
How can I get the latest updates on Corcept Therapeutics?
What role does cortisol play in diseases?
